Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy can be predicted by computed tomography quantified sarcopenia

Eur J Surg Oncol. 2018 Nov;44(11):1818-1823. doi: 10.1016/j.ejso.2018.07.060. Epub 2018 Aug 11.

Abstract

Background: Malnutrition is associated with increased postoperative morbidity in abdominal surgery. This study aimed to determine if sarcopenia and/or abdominal fat composition could predict postoperative outcomes for patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for pseudomyxoma peritonei (PMP) and peritoneal mesothelioma (PM).

Methods: All patients who underwent a complete CRS-HIPEC for PMP and PM, between January 2009 and September 2017, were retrospectively studied. Preoperative computed tomography (CT) was used to measure the cross-sectional surface of skeletal muscle mass and adipose tissue (visceral and subcutaneous), at the level of the third lumbar vertebrae, to assess for sarcopenia and abdominal fat composition.

Results: Among 115 patients, 82 were treated for PMP and 33 for PM. 64 patients (55.7%) were sarcopenic on the preoperative imagery. Major postoperative complications occurred in 63 patients (54.8%), without observable difference between sarcopenic and non-sarcopenic patients (56.2% vs. 52.9%; p = 0.723). The median overall survival (OS) was 73.3 for the patients with a normal muscle mass and 57.2 months for the sarcopenic patients (p = 0.05).

Conclusion: CT measured sarcopenia is an independent predictive factor for overall survival in patients treated for PMP and PM with CRS-HIPEC, but cannot predict postoperative morbidity.

Keywords: Mesothelioma; Peritoneal metastases; Pseudomyxoma peritonei; Skeletal muscle mass.

MeSH terms

  • Abdominal Fat / diagnostic imaging*
  • Adolescent
  • Adult
  • Aged
  • Combined Modality Therapy
  • Cytoreduction Surgical Procedures / methods*
  • Female
  • Humans
  • Hyperthermia, Induced / methods*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / therapy*
  • Male
  • Mesothelioma / mortality
  • Mesothelioma / therapy*
  • Mesothelioma, Malignant
  • Middle Aged
  • Peritoneal Neoplasms / mortality
  • Peritoneal Neoplasms / therapy*
  • Predictive Value of Tests
  • Pseudomyxoma Peritonei / mortality
  • Pseudomyxoma Peritonei / therapy*
  • Retrospective Studies
  • Sarcopenia / diagnostic imaging*
  • Survival Rate
  • Tomography, X-Ray Computed*